Drugs / bone marrow progenitor cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00254722 | Apr 2006 → Nov 2008 | traumatic brain injury | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1 | NCT00128258 | May 2005 → Dec 2016 | congestive heart failure | Amit, Patel N, M.D. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bone marrow progenitor cells | “single intravenous infusion of bone marrow progenitor cells - target dose is 6x10\^6 mononuclear cells/kg body weight, administered within 36 hours of injury” NCT00254722 ↗1“injecting bone marrow progenitor cells (BMPCs) from one's own hip bone into one's heart muscle” NCT00128258 ↗ |
| Known as | BMPCs | “injecting bone marrow progenitor cells (BMPCs) from one's own hip bone into one's heart muscle” NCT00128258 ↗ |
| Modality | Cell therapy | “bone marrow progenitor cell (BMPC) autologous transplantation” NCT00254722 ↗ |
| Route | Other | “direct injection into their hearts” NCT00128258 ↗ |